BTS India Private Equity invests in Parabolic Drugs LimitedMay 6th, 2008 - 6:47 pm ICT by admin
Mumbai, May 6 (ANI -Business Wire India): BTS India Private Equity Fund Limited has announced that it will invest around seven million dollars in Parabolic Drugs, a fast growing pharmaceutical company based out of Chandigarh.
The capital will be used for funding Parabolic’s next level of growth and will be largely used for significantly expanding capacities for its existing and new products.
With this, the Fund managed by Swiss based BTS Group has completed yet another investment in pharmaceutical sector which is one of its preferred sectors. Several of the pharmaceutical companies invested through its earlier Fund have been doing exceedingly well and some of these have been nominated by CNBC TV18, ICICI Bank and CRISIL for the SME awards.
Parabolic Drugs, which has facilites at Derabbasi and Panchkula near Chandigarh, has already established itself with several global pharmaceutical companies as an important supplier for APIs and bulk drugs ranging across several products in the betalactum and cephalosporins range.
“The current round of capital raising is a step towards further broadening the product and customer base, and take the company towards its target of crossing Rs. 10 billion in sales over the next couple of years,” said Pranav Gupta, Chairman and Managing Director of Parabolic.
The company has obtained type II USFDA approval and Certificate of Suitability for some of its products. It is currently in the process of filing several DMFs and CEPs for further strengthening its exposure to the regulated markets both in Europe and US. Going forward, it also plans to enter non beta lactum products in the next two to three years. The company has set up a dedicated research and development centre in line with its plan for future growth.
According to Mr K Srinivas, Managing Partner, BTS “Parabolic has, over the years witnessed rapid growth and has become a leading supplier of APIs to its global customers. We are excited about partnering with Parabolic, which has a long term strategy of becoming a preferred supplier of its products to global customers both in the regulated markets in Europe and US. We are bullish on the Indian pharmaceutical sector and its continued sustained growth.”
YES Bank was the sole strategic advisor to Parabolic for the transaction. (ANI)
- Orchid Chemicals sells penicillin, penem business to Hospira - Aug 29, 2012
- US health regulator approves Chennai drug plant - Jun 22, 2011
- Orchid Chemicals to invest Rs.200 crore this fiscal - Jul 29, 2011
- Orchid Chemicals' plant shut on pollution concerns - Jul 11, 2011
- Vivimed Labs acquire Uquifa for $55 million - Dec 01, 2011
- Goose launches pharma project management solution - May 21, 2012
- Goose launches Artwork Manager for pharma industry - Jan 03, 2012
- Dr Reddy's launches anti-asthma tablets in US - Nov 20, 2010
- Pharma company Granules India's net profit up 42 percent - Jan 24, 2012
- Regulate foreign investment for cheaper medicines: Azad - Nov 01, 2010
- India clears 22 FDI proposals worth $112.5 million - Apr 20, 2012
- Orchid Pharma to invest Rs.200 crore in niche segment - Nov 04, 2010
- Competition check for FDI in pharma will help consumers: CUTS - Oct 11, 2011
- Granules India's revenues rise 37 percent - Apr 24, 2012
- Ranbaxy, Russian region sign healthcare pact - Jan 31, 2011
Tags: apis, bts, bulk drugs, ceps, certificate of suitability, cnbc, cnbc tv18, crisil, dedicated research, dmfs, global customers, icici bank, k srinivas, pharmaceutical companies, pharmaceutical company, pharmaceutical sector, pranav gupta, private equity fund, target, usfda